Liver impairment study tests cancer drug safety
NCT ID NCT06740799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the cancer drug quizartinib behaves in people with severe liver impairment compared to healthy volunteers. Twelve participants will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor for side effects. The goal is to understand dosing safety, not to treat any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Quizartinib (a cancer drug, brand name VANFLYTA)
What this could lead to
If successful, this study could help doctors understand how to safely dose quizartinib in patients with severe liver problems.
What could go wrong
This is a very early, small study (12 people) focused on safety and drug levels, not treatment. It may not lead to any changes in clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Pharma
RECRUITINGMiami, Florida, 33147, United States
-
Clinical Pharmacology of Miami, LLC
RECRUITINGMiami, Florida, 33014, United States
-
GCP Research
RECRUITINGSt. Petersburg, Florida, 33705, United States